<중위건위> "Clinical Trials of Ebola Treatments and Others as New Coronavirus Therapeutics"

[Asia Economy Reporter Jeong Hyunjin] Chinese health authorities announced on the 3rd that they have begun clinical trials related to the development of a treatment for the novel coronavirus infection (Wuhan pneumonia).

Song Suli, spokesperson for the National Health Commission of China (NHC), responded to questions about the progress of new drug development for the novel coronavirus at a press conference on the same day. Spokesperson Song said, "We are currently collecting clinical information data through clinical trials," adding, "Recently, several medical institutions have been conducting clinical trials on the new drug Remdesivir, studying its safety and efficacy."

Remdesivir is an Ebola treatment developed by the American pharmaceutical company Gilead Sciences, and this drug has not yet been approved in the United States.

Earlier, Gilead Sciences announced last month that it is discussing the experimental administration of Remdesivir for novel coronavirus infection together with researchers and medical staff in the United States and China. Although this treatment failed to prove its effectiveness in treating Ebola infection in clinical studies, Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), claimed that it has the potential to be effective against novel coronavirus infection.

This content was produced with the assistance of AI translation services.